Sodium Glucose Co-Transporters Inhibitors as Better Alternative to Immunosuppressive Drugs in Management of Chronic Glomerulonephritis

¹Nephrology Unit, Internal Medicine Department, School of Medicine, Cairo University, Egypt

²Endocrinology Unit, Internal Medicine Department, School of Medicine, Cairo University, Egypt

³Rheumatology and Rehabilitation Department, School of Medicine, Cairo University, Egypt

*Corresponding author: Prof. Usama AA Sharaf El Din, Nephrology Unit, Internal Medicine Department, School of Medicine, Cairo University, 58^th Abbas El Akkad St., Nasr City, Cairo, Egypt, Tel: +201016862000, Fax: +20222753890, E-mail: [email protected]

Received Date: March 25, 2024

Published Date: May 24, 2024

Citation: Sharaf El Din UAA, et al. (2024). Sodium Glucose Co-Transporters Inhibitors as Better Alternative to Immunosuppressive Drugs in Management of Chronic Glomerulonephritis. Mathews J Urol Nephrol. 6(2):19.

Copyrights: Sharaf El Din UAA, et al. © (2024).

ABSTRACT

Treatment of most cases of CGN is based, most of the time, on steroids and a wide scale of other immunosuppressive (IS) agents. In the last 2 years, the anti-diabetic sodium glucose co-transporters inhibitors (SGLT2Is) have shown a significant impact on the rate of progression of chronic renal disease. Many of the cases included in these studies were suffering from focal segmental glomerulosclerosis (FSGS) or IgA nephropathy (IgAN). These results should stimulate the Nephrologists to use SGLT2Is instead of IS agents in the management of different subtypes of CGN. This review illustrates the value of SGLT2Is in different types of CGN.

Keywords: Chronic Glomerulonephritis, Empagliflozin, Canagliflozin, Dapagliflozin, Focal Segmental Glomerulosclerosis, FSGS, IgA Nephropathy, Membranoproliferative Glomerulonephritis, MPGN, Membranous Glomerulonephritis, MGN, Lupus Nephritis, LN.